Abstract

Parent-of-origin imprints have been implicated in the regulation of neural differentiation and brain development. Previously we have shown that, despite the lack of a paternal genome, human parthenogenetic (PG) embryonic stem cells (hESCs) can form proliferating neural stem cells (NSCs) that are capable of differentiation into physiologically functional neurons while maintaining allele-specific expression of imprinted genes. Since biparental ("normal") hESC-derived NSCs (N NSCs) are targeted by immune cells, we characterized the immunogenicity of PG NSCs. Flow cytometry and immunocytochemistry revealed that both N NSCs and PG NSCs exhibited surface expression of human leukocyte antigen (HLA) class I but not HLA-DR molecules. Functional analyses using an in vitro mixed lymphocyte reaction assay resulted in less proliferation of peripheral blood mononuclear cells (PBMC) with PG compared with N NSCs. In addition, natural killer (NK) cells cytolyzed PG less than N NSCs. At a molecular level, expression analyses of immune regulatory factors revealed higher HLA-G levels in PG compared with N NSCs. In line with this finding, MIR152, which represses HLA-G expression, is less transcribed in PG compared with N cells. Blockage of HLA-G receptors ILT2 and KIR2DL4 on natural killer cell leukemia (NKL) cells increased cytolysis of PG NSCs. Together this indicates that PG NSCs have unique immunological properties due to elevated HLA-G expression.

Highlights

  • Mammalian parthenogenetic (PG) embryos undergo early developmental demise and do not develop to full term

  • In contrast to N-derived cells, PG neural stem cells (NSCs) exhibit elevated expression of human leukocyte antigen (HLA)-G and thereby inhibit both the proliferation of peripheral blood mononuclear cells (PBMC) and cytolytic activity of natural killer cell leukemia (NKL) cells

  • PG human embryonic stem cells (hESCs) exhibited typical hESC morphology, expressed pluripotencyrelated markers and formed neural rosettes and NSCs when subjected to a multistep differentiation protocol (Figures 1A, B, Supplementary Figure 1) as described previously [12]

Read more

Summary

Introduction

Mammalian parthenogenetic (PG) embryos undergo early developmental demise and do not develop to full term. PG human embryonic stem cells (hESCs) can be established from blastocysts originating from unfertilized oocytes that have been activated artificially [1,2,3,4,5]. PG hESCs contain genetic material exclusively from the oocyte donor. PG hESC derived from human leukocyte antigen (HLA) heterozygous donors can be both HLA heterozygous and homozygous; and the induction of haploidy during oocyte activation protocols can be utilized to generate HLA homozygous PG hESC [6,7]. Homozygous PG hESCs may serve as an alternative for immunomatched therapies for a large population of patients [8].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call